Tetragon Partners GP Ltd: NEKTAR THERAPEUTICS (NKTR): Quarterly 13F Position History
As of Q1 2026, Tetragon Partners GP Ltd reported 103,037 shares of NEKTAR THERAPEUTICS (NKTR), worth $7.4M and representing 1.5% of its 13F equity book. Quarter-over-quarter share count change: + 33,750 (+48.7%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 103,037Shares Held (Latest Filing)
- $7.4MReported Market Value (Latest Filing)
- 1.5%Portfolio Weight (% of 13F Equity Book)
- +33,750Quarter-over-Quarter Share Change
- +$4.5MQuarter-over-Quarter Value Change
- 103,037Peak Reported Shares (Historical)
Recent initiation: Tetragon Partners GP Ltd first reported NKTR on the Q4 2025 filing — fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 103,037 | +33,750 | +48.7% | $7.4M | 1.5% | $72.0 |
| Q4 2025 | 69,287 | — | — | $2.9M | 0.6% | $42.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tetragon Partners GP Ltd first disclose a NKTR position in 13F-HR filings?
Tetragon Partners GP Ltd first reported NEKTAR THERAPEUTICS (NKTR) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Tetragon Partners GP Ltd's most recent quarter-over-quarter share-count change in NKTR?
Between Q4 2025 and Q1 2026, Tetragon Partners GP Ltd added 33,750 shares of NKTR (+48.7%), bringing the total reported position to 103,037 shares at a market value of $7.4M.
Does the implied price-per-share represent Tetragon Partners GP Ltd's cost basis in NKTR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.